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Background: Synthetic lethality is an appealing technique for selectively targeting cancer cells which have
acquired molecular changes that distinguish them from normal cells. High-throughput RNAi-based screens have
been successfully used to identify synthetic lethal pathways with well-characterized tumor suppressors and
oncogenes. The recent identification of metabolic tumor suppressors suggests that the concept of synthetic
lethality can be applied to selectively target cancer metabolism as well.
Results: Here, we perform a high-throughput RNAi screen to identify synthetic lethal genes with fumarate
hydratase (FH), a metabolic tumor suppressor whose loss-of-function has been associated with hereditary
leiomyomatosis and renal cell carcinoma (HLRCC). Our unbiased screen identified synthetic lethality between FH
and several genes in heme metabolism, in accordance with recent findings. Furthermore, we identified an
enrichment of synthetic lethality with adenylate cyclases. The effects were validated in an embryonic kidney cell line
(HEK293T) and in HLRCC-patient derived cells (UOK262) via both genetic and pharmacological inhibition. The
reliance on adenylate cyclases in FH-deficient cells is consistent with increased cyclic-AMP levels, which may act to
regulate cellular energy metabolism.
Conclusions: The identified synthetic lethality of FH with adenylate cyclases suggests a new potential target for
treating HLRCC patients.
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Until recently, the identification of synthetic lethal inter-
actions in human cells was based on screens using
chemical libraries or on inferred synthetic lethality in
model organisms such as S. cerevisiae [1]. Recent ad-
vances in RNAi technology have enabled systematic
screening for synthetic lethal interactions in human
cells. This was done either by a traditional forward or
backward genetics approach [2]. In forward genetics,
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ity identified based on correlation between a specific
genetic change and sensitivity to specific gene knock-
down. The backward genetics approach involves the
generation of a pair of isogenic cell lines with a specific
genetic change and the consequent screening of both
cell lines for their response to gene knockdowns. The ac-
tual screen for gene knockdown effects is performed ei-
ther individually for each short hairpin RNA vectors
(shRNA), or by pooling them together using molecular
barcode techniques [2]. Such approaches have recently
been applied to identify synthetic lethal partners with
central oncogenes and tumor suppressors, such as p53,
RAS, BRCA, and VHL, all major regulators of cancer
signaling pathways [3-7].ral Ltd. This is an Open Access article distributed under the terms of the Creative
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that affect metabolic enzymes suggests that the concept of
synthetic lethality may be successfully applied to target can-
cer metabolism [8-11]. Such genetic mutations include the
identification of two metabolic tumor suppressors in TCA
cycle, fumarate hydratase (FH) and succinate dehydrogen-
ase (SDH), and oncogene, isocitrate dehydrogenase (IDH),
as well as other passenger loss-of-function mutations
[8-10]. Loss-of-function mutations in FH have been associ-
ated with a number of diseases including hereditary leio-
myomatosis and renal cell carcinoma (HLRCC), a cancer
syndrome characterized by a malignant form of renal can-
cer [12]. A recent study by Frezza et al. combined experi-
mental metabolomics and computational modeling to
identify a metabolic shift that occurs in FH deficient cells,
characterized by a truncated TCA cycle and diversion of
glutamine-derived carbons into the heme biosynthesis and
degradation pathway [11]. Of note, the inhibition of this
pathway selectively affected the viability of FH-deficient
cells, while sparing the FH-proficient counterpart. While
this represents a promising application of metabolic syn-
thetic lethality, no high-throughput screening for synthetic
lethality has been performed so far.
Here, we perform a high-throughput screen for genes
that are synthetic lethal with FH in a human FH-silenced
embryonic kidney cell line (HEK293T), utilizing an RNAi li-
brary targeting over 10,000 candidate genes. Our unbiased
screen revealed that several genes in the heme metabolism
are synthetic lethal with FH, in accordance with previous
findings [13]. Furthermore, we identified an enrichment of
synthetic lethal interactions with adenylate cyclases. We
validated these findings in HEK293T and in FH-deficient
HLRCC-patient derived cells (UOK262) via both genetic
and pharmacological inhibition and demonstrated that that
the FH-deficient cells are characterized by an increased
turnover of cAMP.
Results
Utilizing pooled RNAi screen to identify synthetic lethality
with FH
To identify genes that are synthetic lethal with FH,
we applied an approach that combines the pooled
shRNA silencing of 10,000 different genes with siRNA
silencing of FH in a FH-proficient embryonic kidney
cell-line HEK293T (Figure 1A). HEK293T cells were
transduced with a library of shRNA agents with an
average of 5 agents per gene (lentiviral 55 K Decipher
shRNA expression library. Cellecta, Mountain View,
USA). The complete set of genes targeted by the De-
cipher library is shown in Additional file 1. Transduc-
tion with low viral titer (MOI = 0.3) ensured a
maximum of one viral integration event, and hence
one gene knockdown per target cell. Seven days post-
transduction, cells were sub-cultured under twodifferent conditions: One fraction of cells was trans-
fected with siRNA targeting the expression of FH and
another fraction was transfected with a non-targeting
control siRNA. The mRNA levels of FH were initially
reduced to below 30 percent and recovered almost
completely at 120 h post transfection (Figure 1B). On
the other hand, levels of Fumarase, the protein
encoded by FH, were found to be reduced for up to
120 h post transfection (Figure 1C). The reduction of
Fumarase to levels even lower than the ones shown
in Figure 1C lead to cell death (unpublished data),
since Fumarase is essential for the survival of
HEK293T cells. Consequently, we tried to avoid such
low Fumarase levels during the screen. Finally, cells
were harvested and each of the 55 K expression con-
structs was quantified via next-generation sequencing
of associated molecular barcode tags. Cells that
expressed a synthetic lethal shRNA with FH would
consequently be depleted in the siFH pool compared
to siCTRL pool (Figure 1A). We then computed the
ratio of abundances of each shRNA between the siFH
the siCTRL and pools. A complete list of shRNA ex-
pression constructs together with the corresponding
abundance ratios is shown in Additional file 2. We
consider a gene as a candidate to be synthetic lethal
with FH if the ratio of abundances for at least half of
the shRNA agents targeting the gene is lower than a
threshold. In order to account for screen specific
‘noise’ levels, this threshold was computed from the
standard deviation of abundance ratios obtained from
twenty-one shRNA agents targeting a negative control
(Luciferase). Out of the total 10,455 genes analyzed,
340 candidate synthetic lethal genes were found
(Additional file 3).
Next, we searched for pathways that are significantly
enriched with candidate FH-synthetic lethal genes. Inter-
estingly, we found 7 KEGG and Reactome enriched
pathways (Table 1). Among these pathways, heme me-
tabolism and in particular HMOX2, FECH, UGT1A3,
UGT2A3 were found to be synthetic lethal with FH, in
striking accordance with previous observations by Frezza
et al. [11]. Another pathway enriched with candidate
synthetic lethal genes with FH is the ‘metabolism of car-
bohydrates’ pathway, consisting of glucose transporter
SLC2A1 and three glycolytic enzyme coding genes,
TALDO1, ENO3, PKLR. This pathway enrichment is
consistent with an increase in glucose uptake and glyco-
lytic flux due to FH deletion, as has previously been
demonstrated [11,14]. The pathway showing the highest
enrichment of synthetic lethal genes is ‘GABA B recep-
tor activation’, consisting of four adenylate cyclase genes
ADCY3, ADCY6, ADCY7 and ADCY9 (out of a total of
ten known adenylate cyclase genes). Given these surpris-
ing findings, we decided to focus on validating the
Figure 1 Schematic of RNAi screen with analysis of fumarate levels throughout the screen. (A) Schematic of FH synthetic lethality
screening strategy. Briefly, the screen involves three steps: (i) cell transduction with a library of shRNA agents; (ii) splitting the culture and
silencing FH in one subculture; (iii) quantifying shRNA agent abundance by means of barcode sequencing. The expression of different shRNAs
can have lethal (red), synthetic lethal (yellow), synthetic rescue (blue), or no effect (green) on the proliferation of each cell during the screen. (B)
Residual FH mRNA levels at indicated times post siRNA transfection. (C) Residual FH protein level at indicated times post siRNA transfection.
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effect of FH deletion on cyclic-AMP level.
Genetic validation of synthetic lethality between
adenylate cyclase and FH in the embryonic kidney cell
line, HEK293T
To gain insight into why FH-synthetic lethality was found
specifically with ADCY3, ADCY6, ADCY7 and ADCY9
among the 10 known adenylate cyclase genes, we examined
adenylate cyclase expression in HEK293T. Interestingly, we
found that these four genes have the highest expression
level among all adenylate cyclases, with the exception of
ADCY1 (Figure 2A). Of note, we observed that 2 out of 5
shRNA constructs targeting ADCY1 actually do show a
synthetic lethal effect with FH, while the abundance of a
third shRNA agent is borderline significant (Figure 2B).
Overall, these results suggest that the silencing of the most
expressed adenylate cyclase, irrespective of their specific
isoform, strongly affects the survival of FH-deficient cells.
To confirm the synthetic lethality between adenylate
cyclases and FH, the two highest ranking shRNAsidentified by the primary screen, targeting the expression
of ADCY3, ADCY6, ADCY7 or ADCY9, were individu-
ally sub-cloned into the library expression vector pRSI9
(shRNA sequences are shown in Additional file 4). Cells
were co-transduced with lentiviruses containing
shADCY expression constructs as well as a shRNA ex-
pression construct targeting FH. At 6 days post trans-
duction, expression levels of FH as well as of adenylate
cyclases, and cell viability of the cells were determined
relative to control cells. Two shRNAs targeting the ex-
pression of ADCY3 as well as one shRNA targeting each
ADCY6 and ADCY7 were confirmed to be synthetic le-
thal with FH in HEK293T cells (Figure 2C). In all cases,
the shRNA targeting led to approximately 50 percent re-
duction in gene expression levels (Figure 2D).
Genetic and pharmacological validation of synthetic
lethality between adenylate cyclases and FH in the
HLRCC-patient derived cell line UOK262
To further validate synthetic lethality between adenylate
cyclase and FH, we used tumor cells harboring a
Table 1 REACTOME and KEGG pathways enriched with candidate FH-synthetic lethal genes
Pathway Genes p-value
REACTOME_GABA_B_RECEPTOR_ACTIVATION ADCY3, ADCY6, ADCY7, ADCY9, GNG3, KCNJ4, GNG4 0.0001
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION BMPR1B, CCL22, CSF3, CXCR6, EGF, GH1, IL1RAP, IL22, INHBB, LTA,
TNFRSF10D, TNFRSF11A, TNFRSF1B, TNFSF13B, TNFSF8, EDA2R,
TNFSF15
0.0024
REACTOME_G_BETA_GAMMA_SIGNALLING_THROUGH_PI3KGAMMA GNG13, GNG3, PIK3CG, GNG4 0.0035
KEGG_APOPTOSIS BCL2L1, CASP6, IL1RAP, IRAK1, MAP3K14, PIK3CG, PRKX, TNFRSF10D 0.0072
REACTOME_MHC_CLASS_II_ANTIGEN_PRESENTATION ARF1, DNM2, OSBPL1A, CTSC, KIF20A 0.0303
KEGG_PORPHYRIN_AND_CHLOROPHYLL_METABOLISM FECH, HMOX2, UGT1A3, UGT2A3 0.0432
REACTOME_METABOLISM_OF_CARBOHYDRATES ABCC5, B4GALT3, ENO3, KERA, PC, PKLR, PYGM, SLC2A1, BCAN,
NUP205, SLC25A12, TALDO1
0.0453
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a metastatic cell line derived from an HLRCC patient
[15]. Of note, these cells are devoid of any FH activity
and show similar metabolic features to Fh1-deficient
mouse cells [13]. Specifically, we silenced ADCY3,
ADCY6, ADCY7 and ADCY9 expression and measured
colony formation both in UOK262 and in an isogenic
cell line in which FH was reintroduced (UOK262pFH)
[11]. Of note, we found that ADCY6, ADCY7 and
ADCY9, but not ADCY3 were synthetic lethal with FH
(Figure 3A). Since these results are in partial agreement
with our findings in FH-deficient HEK293T cells, weFigure 2 Adenylate cyclases are synthetic lethal with FH in HEK293T
(B) Ratios of shRNAs targeting all ten known adenylate cyclase genes, as d
certain shRNA under siFH vs siCTRL conditions. Negative values indicate de
threshold defined by the distribution of twenty-one negative control shRN
marked in blue, at least half of the shRNA agents targeting them were dep
synthetic lethal with FH. shRNA dot colors: yellow: synthetic rescue, black: n
HEK293T cells (shFH) and HEK293T expressing endogenous levels of FH (sh
HEK293T cells were co-transduced with shFH and shADCY shRNA expressio
targeted genes after 6 days of expression of indicated shRNA.analyzed adenylate cyclase expression data measured by
qPCR in UOK cells. Interestingly, we found that
ADCY6, ADCY7, and ADCY9 are the most abundant
adenylate cyclase in UOK262 cells, while ADCY3 is very
poorly expressed in these cells. These results strongly
suggest that targeting the most abundant adenylate cy-
clases is again sufficient to affect cell viability of FH-
deficient cells (Figure 3B).
Next, we wanted to confirm synthetic lethality be-
tween adenylate cyclases and FH using a pharmaco-
logical approach. To this end, we tested the effects of
the adenylate cyclase inhibitor MDL-12,330A on thecells. (A) Expression levels of adenylate cyclase genes in HEK293T cells.
etermined from the primary screen. Ratios indicate the abundance of a
pletion, positive values indicate enrichment. Dotted line indicates
As in order to distinguish background noise from real hits. For genes
leted below threshold and hence these genes were considered
o synthetic effect, blue: synthetic lethal. (C) Viability of FH-impaired
CTRL) determined after 6 days of expression of indicated shRNA.
















































































































Figure 3 Inhibition of adenylate cyclases is more toxic to FH-deficient than to FH-expressing HLRCC cells. (A) Colony formation in
UOK262 versus UOK262pFH after the infection with the indicated shRNA. (B) Gene expression level of adenylate cyclase genes in UOK262 and
UOK262pFH. (C) Colony formation following treatment of UOK262 and UOK262pFH cells with indicated concentrations of the adenylate cyclases
inhibitor MDL-12,330A. (D) Representative images of a colony survival assay of UOK262 and UOK262pFH after the treatment with 1 μM
MDL-12,330A for 7 days.
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creasing concentrations of 0.5, 1 and 5 μM MDL-
12,330A for 7 days, after which colonies were counted
(Figure 3C). It was found that UOK262 cells were more
sensitive to this adenylate cyclase inhibitor than their FH
reconstituted UOK262pFH counterparts. Particularly, at
a concentration of 1 μM MDL-12,330A we found that
UOK262 cells formed less than half as many colonies as
UOK262pFH cells (Figure 3C and D).
Cyclic-AMP production is increased following FH deletion
and supported by a drop in nucleotide phosphodiester
expression
The synthetic lethality between adenylate cyclase and FH
suggests that cyclic-AMP (cAMP) mediated signaling
pathways may play an important role in the survival of
FH-deficient cells. Therefore, we investigated the possibil-
ity that cAMP homeostasis is deregulated in these cells by
measuring cAMP levels in UOK262. Our analysis revealed
that steady-state levels of cAMP are maintained very low
in both FH-deficient and proficient cell lines (Figure 4A).
Nevertheless, when cells were stimulated with the adenyl-
ate cyclase activator forskolin alone or in combination
with the pan-inhibitor of phosphodiesterases (PDEs)IBMX, the capacity for cyclic-AMP production of
UOK262 cells was higher than that of UOK262pFH, sug-
gesting a higher cAMP turnover in FH-deficient cells.
Notably though, these results may be biased due to the
existence of distinct cAMP pools of mitochondria and
cytoplasm [16].
To examine the mechanism that leads to an increased
cAMP turnover in the FH deficient cells, we analyzed
the expression of adenylate cyclase and cAMP phospho-
diesterase (PDE) genes in UOK262 and UOK262pFH
cells using Gene Set Enrichment Analysis (GSEA) [17].
We found that while there is no significant change in
adenylate cyclase gene expression following FH deletion,
the expression of cAMP phosphodiesterase genes signifi-
cantly drops following FH deletion (Figure 4B-C). To
further evaluate the potential importance of cAMP
phosphodiesterase for increasing cAMP production, we
reexamined the effect of PDEs knockdowns in the syn-
thetic lethality screen. Importantly, we found that the
knockdown of 2 out of 9 cAMP phosphodiesterase
(PDE1B and PDE7A) showed a synthetic rescue effect,
representing a significant enrichment of PDEs as FH-
synthetic rescue genes (hypergeometric p-value = 0.047).
Hence, the knockdown of either PDE1B or PDE7A leads
AB
C
Figure 4 Increase in cyclic-AMP production following FH
deletion. (A) Cyclic-AMP level in UOK262 versus UOK262pFH following
treatment with the adenylate cyclase activator forskolin alone or in
combination with PDEs inhibitor IBMX. (B-C) Gene set enrichment
analysis (GSEA) of changes in expression between UOK262 versus
UOK262pFH. Specifically, the x-axis represents an ordering of genes
based on their drop in expression following FH deletion. The y-axis
in the upper graph represents the enrichment of increasing sets of
differentially expressed genes with adenylate cyclases (B) or PDEs
(C). As shown, the expression of adenylate cyclases does not
change significantly following FH deletion (B), while the expression
of PDEs significantly drops following FH deletion (C).
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rescue is defined analogously to synthetic lethality, re-
quiring that the ratio of abundances in the siFH versus
the siCTRL pools of at least half of the shRNA agents
targeting the gene are significantly high (Figure 1A;
Methods).
Discussion
In this study we performed a high-throughput screen for
identifying synthetic lethal genes with the tumor sup-
pressor FH, whose loss of function is associated with the
development of renal cancer, with the aim of finding
novel therapeutic targets for this deadly disease. The
method was applied on the FH-proficient embryonic
kidney cell line, HEK293T, and involved the double
knockdown of genes via a library of shRNA constructs
and by means of the direct silencing of FH via siRNA.
Identified synthetic lethality in HEK293T between FH
and adenylate cyclases was shown to be transferable to
FH-deficient HLRCC-patient derived cells (UOK262).
Notably, the screen was not carried out in UOK262 cells,
which represent a more direct model of HLRCC, be-
cause UOK262 and UOK262pFH substantially differ in
terms of proliferation speed, transducibility, knockdown
efficiency, and knockdown kinetics, which would have
influenced the interpretation of the screen results. In-
stead, HEK293T is a more appropriate cell line for such
screens since it can be easily and effectively transfected
and transduced and shows negligible proliferation de-
fects upon acute, partial silencing of FH. Inducing a
stronger and more permanent knockdown or even
knockout of FH might have yielded different screening
results. However, this approach would have required the
identification of a FH-proficient cell line that tolerates
such strong reduction of FH levels for the duration of
the screen (over two weeks). Moreover, the partial re-
duction of FH levels used for this screen, which resulted
in only mild proliferation defects in HEK293T cells,
allowed us to analyze synthetic lethal interactions over a
large dynamic range. In other words, if strong inhibition
of FH by itself would result in severely reduced viability,
it would be hard to identify genes whose inhibition in
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required for the identification of synthetic lethal
interactions.
Besides confirming the crucial role of the heme biosyn-
thesis pathway in FH-deficient cells, this screen revealed
an unexpected result, i.e. synthetic lethality with cAMP
signaling pathway. These findings prompted us to further
investigate the link between FH and cAMP biosynthesis.
Although this link has never been established before in
eukaryotes, FH expression is closely associated with
cAMP signaling in E. Coli, indicating an interesting cross-
talk between these two pathways [18]. Our results suggest
that FH-deficient cells have a higher turnover of cAMP,
which might underline the addiction to cAMP-activated
protein kinases (PKA)-associated oncogenic pathways. In-
deed, PKAs are known to be involved in the regulation of
cell proliferation and have previously been shown to par-
ticipate in the onset and progression of various cancers
[19]. Furthermore, cAMP has previously been shown to
induce HO-1, the limiting step of the heme biosynthesis
and degradation pathway [20]. Therefore, it can be specu-
lated that increased cAMP could also serve to support the
expression of HO-1 [21], which is essential for the survival
of FH deficient cells [13], as also found in our synthetic le-
thality screen. Another hypothesis is that FH deficiency
lowers oxidative TCA cycle activity and hence CO2 and bi-
carbonate levels, while bicarbonate is known to activate
specific adenylate cyclases [22,23]. The down-regulation
of bicarbonate-activated adenylate cycles may potentially
render the activity of other adenylate cyclases essential for
survival. This hypothesis regarding lower bicarbonate levels
in FH deficient cells is supported by a recent study showing
increased dependence of FH deficient cells on reductive
carboxylation of glutamine-derived alpha-ketoglutarate via
isocitrate dehydrogenase [24].Conclusion
Our results suggest adenylate cyclase as a new potential
target for treating HLRCC patients, while the specific
mechanism which renders it essential for the survival of
FH-deficient cells remains an open question.Methods
Cell culture conditions
HEK293T cells were cultured in DMEM (Invitrogen
#41965) supplemented with 10% FCS (Invitrogen #10500)
and 1% penicillin/streptomycin 10,000 U (Invitrogen
#15140). UOK-262 and UOK-262-FH cells were cultured in
DMEM (Invitrogen #21969) supplemented with 2 mM L-
glutamine and 10% FCS. Cells were cultured at 37°C in a
5% CO2 atmosphere. All cell lines were tested via “Multi-
plex cell Contamination Test” as previously described [25].Packaging of lentiviral pool
DECIPHER library human Module 1 (#DHPAC-M1-P)
and human Module 2 (DHDAC-M2-P) were obtained
from Cellecta Inc. (Mountain View, U.S.). For packaging
into lentiviral particles, plasmid DNA from Modules 1
and 2 was co-transfected into HEK293T cells together
with the second generation helper plasmids psPAX2 and
pMD2.G. One day before transfection, HEK293T cells
were seeded into nine 175 cm2 flasks (Greiner Bio One
#660175) at 7.0E + 04 cells per cm2 in standard DMEM
medium with freshly added L-Glutamine (2 mM final)
and without penicillin/streptomycin. At the day of trans-
fection, 60 μg from each Module was mixed with 100 μg
pMD2.G, 200 μg psPAX2 and 600 μl PLUS™ Reagent
(Invitrogen #11514-015) into a total volume of 13 ml
Opti-MEMW (Invitrogen #11058-021). The plasmid mix
was incubated for 15 min at RT before mixing with
14 ml Opti-MEMW containing 900 μl Lipofectamine™
(Invitrogen #18324020). The complete transfection mix
was incubated for another 15 min at RT before adding
2.9 ml to each cell culture flask containing HEK293T
cells. At 24 h post transfection the medium in each cul-
ture flask was replaced by 20 ml high serum DMEM
(30% FCS) containing DNase (1 U/ml, QIAGEN #19101)
and MgCl2 (4 mM). Addition of DNase helps reducing
carryover of plasmid DNA into the viral pool. At 24 h
after addition of high serum medium, the lentivirus con-
taining supernatant was harvested and stored at 4°C. To
each culture flask 20 ml fresh high serum medium were
added and flasks were incubated for an additional 24 h.
Finally, the complete lentiviral harvest was pooled to a
total volume of 360 ml and passed through a 0.45 μm
PES filter (Nalgene #166-0045). Lentiviral pools were
stored in aliquots at −80°C for further use.
Pooled RNAi screen
HEK293T cells were seeded 24 h prior to transduction.
A total of 5.0E + 07 cells were seeded for transduction
with each Module into 25 cell culture flasks the size of
175 cm2. Cells were transduced with the lentivirally
packaged Modules at low multiplicity of infection
(MOI = 0.3) in standard DMEM containing 3.5 μg/ml
PolybreneW (Sigma-Aldrich #107689). As a result, we
anticipate that each of the 27,500 shRNA expression plas-
mids present in each Module integrated into the genome
of 540 individual cells. The viral supernatant was replaced
24 h later with standard DMEM culture medium contain-
ing 2 μg/ml cell culture tested puromycin dihydrochloride
(Sigma-Aldrich #5858-2). Selection was continued for an
additional 5 days after which cells were transferred into
fresh standard DMEM medium without antibiotics and
grown for an additional 24 h. Following this, 2.8E + 07
cells transduced with either Module were transferred into
four new 175 cm2 flasks in standard DMEM without
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in two flasks were transfected with a mix of two siRNAs
targeting the expression of Fumarate Hydratase (siFH)
while cell in the two additional flasks were transfected
with of an AllStars negative control siRNA (siCTRL). For
siFH transfection, 18.5 ml Opti-MEMW containing 1 ml
HiPerfect (QIAGEN #301707) were mixed with 220 μl
siFH_2 (20 μM QIAGEN #SI00002989) and 220 μl siFH_3
(20 μM QIAGEN #SI00002996). For the siCTRL transfec-
tion, 440 μl AllStars negative control siRNA (20 μM QIA-
GEN #1027281) was mixed with identical amounts of
Opti-MEMW and HiPerfect. Both master mixes were
mixed by vortexing and incubated at RT for 10 min. Fi-
nally transfection complexes were added dropwise to two
culture flasks from each Module. At 40 h post-
transfection, cell from each of the four samples (Module1/
siFH, Module1/siCTRL, Module2/siFH, and Module2/
siCTRL) were transferred into 20 cell culture flasks
(175 cm2) in standard DMEM medium at 7,0E + 05 cells
per cm2 and grown for an additional 80 h. By the end of
the screen, cells were harvested and cell pellets from each
sample were stored in three aliquots (~4.0E + 07 cells per
aliquot) at −20°C for further analysis.
Barcode quantification
Cell pellets from each sample were thawed and resus-
pended in 5 ml buffer P1 (QIAGEN #19051) supple-
mented with 100 μg/ml RNase A (QIAGEN #19101) and
0.5% SDS. After 5 min incubation at RT the DNA was
sheared sonicating the cells for 5 sec. Following sonic-
ation genomic DNA was extracted from each sample
using the DNeasy Blood and Tissue Kit (QIAGEN
#69504). Total DNA yield was around 300 μg from each
sample. PCR amplification of barcodes was carried out
in two separate rounds using the TitaniumW Taq PCR
Kit (Clonetech #639211). The reaction composition for
the first round PCR was 10 μl 10× Titanium Taq PCR
Buffer, 8 μl dNTPs (2.5 mM each), 1 μl Titanium Taq,
3 μl FwdHTS Primer (10 μM), 3 μl RevHTS Primer
(10 μM) and 50 μg template genomic DNA adjusted to a
total of 100 μl with PCR-grade water. Four reactions
were prepared from each sample resulting in a total of
200 μg genomic DNA being used for barcode amplifica-
tion. The PCR program for the first round PCR was (1)
94°C for 3 min, (2) 94°C for 30 sec, (3) 65°C for 10 sec,
(4) 72°C for 20 sec, (5) goto (2) 15 times, (6) 68°C for
2 min, (7) 10°C forever. For each sample, the four first
round reactions were pooled and 2 μl of this pool were
used as template for second round PCR. In addition to
the 2 μl template from the first round PCR, the reaction
composition of the second round PCR was 10 μl 10× Ti-
tanium Taq PCR Buffer, 8 μl dNTPs (2.5 mM each), 1 μl
Titanium Taq, 5 μl FwdGEX Primer (10 μM), 5 μl
RevGEX Primer (10 μM) adjusted to a total of 100 μlwith PCR-grade water. The PCR program for the first
round PCR was (1) 94°C for 3 min, (2) 94°C for 30 sec,
(3) 65°C for 10 sec, (4) 72°C for 10 sec, (5) goto (2) 9
times, (6) 68°C for 2 min, (7) 10°C forever. For each
sample three second round PCRs were performed and
every reaction was purified individually using QIAquick
PCR purification Kit (QIAGEN #28106) and eluted in
50 μl elution buffer (EB). Eluted PCR products were ana-
lyzed individually via gel electrophoresis and Nanodrop
ND1000. PCR products were 106 base pairs long for
every reaction and amounts were almost identical. Trip-
licate reactions from each sample were pooled and
purified via gel electrophoresis (3.5% agarose) using
QIAquick Gel Extraction Kit (QIAGEN #28704). Gel ex-
cision was performed without directly staining the
106 bp band with ethidium bromide but smaller bands
which were run alongside with the band for excision.
After gel purification the PCR products were eluted in
2× 10 μl elution buffer, heat denatured at 95°C for 5 min
and placed on ice. The gel purified fragments were ad-
justed to equal concentrations (50 ng/μl). Finally 2 μl of
each fragment were analyzed on a 3.5% agarose gel and
found to be of correct size. Following successful recov-
ery, the barcodes were quantified using a Genome
Analyzer IIx (Illumina) and the GexSeqN sequencing
primer at a final concentration of 500 nM. Barcodes
from Module 1 and Module 2 were sequenced combined
in one lane for siFH or siCTRL respectively. In average
3.0E + 07 reads were sequenced per lane. The sequences
for all primers used are shown in Additional file 5.
Analysis of sequencing data
For quantification of read counts per barcode, the Bar-
code Deconvoluter software was used which is available
for download from the Cellecta website. Read counts of
individual barcodes were normalized to the average read
count in each lane to adjust for varying total read counts
in different sequencing lanes. Barcodes with less than
100 reads in the control lane were excluded from ana-
lysis (Module 1 = 2.3%; Module 2 = 2.7%). From the
remaining barcodes the ratios between read counts after
FH knockdown and negative control were calculated. All
log2 ratios used for further analysis are shown in
Additional file 2. Each module included twenty-one
negative control shRNA expression constructs targeting
the gene Luciferase (Luc) for knockdown. The mean
standard deviation from those constructs was calculated
as an estimate of variance in the screen. Standard devia-
tions were 0.1595 and 0.1863 for Modules 1 and 2, re-
spectively. Expression constructs with log2 ratios lower
than the negative standard deviation of Luciferase con-
structs were considered to be specifically depleted in the
FH knockdown sample. The number of constructs per
gene that passed those filter criteria was counted. Genes
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were targeted by, were considered as potentially syn-
thetic lethal interaction partners of FH. In total 340
genes (Additional file 3) out of the 10,455 genes targeted
by both Modules (Additional file 1) were considered as
candidate genes and used for signaling pathway analysis.
Pathway enrichment analysis of candidate synthetic lethal
genes
A hypergeometric test was used to compute an enrich-
ment p-value for 861 KEGG and Reactome pathways.
P-values were FDR corrected for multiple testing. Sig-
nificantly overlapping pathways were filtered by itera-
tively going over the list of pathways (sorted by FDR
corrected p-value), removing pathways with more than
50% overlap with previous pathways in the list.
Cloning of shRNA expression constructs
Candidate oligonucleotide sequences were synthesized
and desalted (Sigma). Sequences are shown in Additional
file 4. At 5′ the guide strand was synthesized with an
additional ACCG overhang and the passanger strand
with CGAA to allow subsequent cloning into the BpiI
(Fermentas #ER1011) digested pRSI9 vector. Following
phosphorylation (T4 PNK, Fermentas #EK0031) and an-
nealing of guide and passanger strand (99°C to 4°C at
−0.1°C per second) the double stranded oligonucleotides
were ligated into BpiI digested pRSI9 vector with T4 lig-
ase (Fermentas #EL0011) for 1 h at RT. Ligated plasmids
were transformed into chemically competent E. coli
(strain STBL3) using standard heat shock protocol.
Transformed E. coli were transferred onto agar plates
supplemented with 100 μg/ml carbenicillin and incu-
bated at 37°C overnight. Single clones were used to in-
oculate 5 ml LB (100 μg/ml carbenicillin). After 18 h at
37°C with shaking at 200 rpm, plasmids were isolated
using QIAprep Spin Miniprep Kit (QIAGEN #27106).
Purified plasmids were checked for correctly inserted se-
quences via sequencing (GATC) with FwdU6 primer.
From E. coli cultures harboring the correct plasmid, gly-
cerol stocks were prepared and stored at −80°C for fur-
ther use.
Quantitative real-time PCR
Cells were pelleted and total RNA was extracted using
Qiagen RNeasy Mini Kit (QIAGEN #74104). RNA
concentration was adjusted to 50 ng/μl. The OneStep
RT-PCR Kit (QIAGEN #210210) was used according to
instructions in the manual and reactions were prepared
in a 384 well format with 50 ng template per well. QIA-
GEN QuantiTect primer shown in Additional file 5 were
used. Reactions were run on run on a LightCycler 480
(Roche).Western blotting
Samples were run on a 10% SDS-PAGE gel and blotted on
nitrocellulose membrane. Primary antibodies were incu-
bated overnight at 4°C. FH antibody (Sigma #2500433) was
diluted 1:10,000 and beta-actin antibody (Sigma #A3853)
was diluted 1:5,000. Secondary horseradish peroxidase con-
jugated antibodies were incubated for 1 h at RT. Anti-goat
was diluted 1:5,000 and anti mouse was diluted 1:2,000.
Viability assays
Cells were seeded into 96 well plates at 600 cells per well
and transduced at MOI > 1 in appropriate cell culture
medium supplemented with 5 μg/ml polybrene. At 6 days
post transduction, cell culture medium was replaced by
50 μl medium containing 20 μg/ml resazurine (Acros
Organics #418900010). Following incubation fluorescence
intensity was detected (Ex = 544 nm/Em =590 nm).
Colony formation assay
Colony formation assays were performed using a modified
version of the sulforhodamine B colorimetric protocol de-
veloped by Vichai & Kirtikara, [26]. 600 cells were plated in
triplicate into 6-well plates infected with lentiviral particles
against the indicated genes or treated with the indicated
doses of adenylate cyclase inhibitor MDL-12,330A. At the
end of the treatment cells were allowed to recover for 4 days
and then fixed using trichloroacetic acid (TCA) at the final
concentration of 3% followed by 1 h incubation at 4°C. The
plates were washed four times with water before being
allowed to air-dry at room temperature overnight. Colonies
were stained by incubation with 1 ml 0.05% (wt/vol) sulfor-
hodamine B solution in 1% (vol/vol) acetic acid for 30 min.
Unbound dye was removed and the plate washed four
times with 1% (vol/vol) acetic acid. Colonies were counted
manually and by a ColCount automated colony counter
(Oxford Optronix).
cAMP ELISA
2 × 105 cells were plated onto 6-well plates and cultured
in standard medium for 12 h. The medium was replaced
with fresh medium supplemented with drugs at the indi-
cated concentrations or DMSO at the maximal concen-
tration used in the drug treatments. At the end of the
incubation period, cells were lysed with 250 μl 0.1%
DMSO in 0.1 M HCl for 20 min at room temperature.
The lysate was centrifuged at 1,000 × g for 5 min and
the supernatant split for protein quantification by BCA
assay (20 μl) and cAMP quantification (200 μl). The
cAMP levels were quantified using the Direct cAMP
ELISA kit (Enzo Life Sciences) following manufacturer’s
instructions. Absorbance at 405 nm (A405) was detected
using an Infinite 200 PRO plate reader (Tecan). The
average A405 from blank wells was subtracted from all
other wells and the cAMP concentration of samples was
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to cAMP standards before normalising by the total pro-
tein concentration in each sample. In each individual ex-
periment, drug treatments were performed in triplicate
and the cAMP and protein quantifications for each sam-
ple were performed in duplicate.
Availability of supporting data
The complete set of microarray expression data used for




Additional file 1: Genes included in Decipher library Modules 1 and
2 with Refseq numbers.
Additional file 2: All shRNA constructs included in Decipher library
Modules 1 and 2 with Cellecta_IDs, total barcode read counts per
construct as well as computed log2 fold change ratios from barcode
abundances in siFH/siCTRL conditions.
Additional file 3: Genes identified to act synthetically lethal with FH.
Additional file 4: Sequences of shRNAs targeting candidate genes.
Additional file 5: Sequences of primers used for quantification of
barcode abundance and primers used for qRT-PCR.
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